Agnieszka Wozniak, PhD (she/her/hers)

Associate Professor
Laboratory of Experimental Oncology, KU Leuven, Leuven Cancer Institute, Belgium

Agnieszka Wozniak, PhD is a molecular biologist with a comprehensive expertise in pharmacology, molecular biology, and (pre)clinical drug testing. Currently she is Associate Professor in the Laboratory of Experimental Oncology, Department of Oncology, KU Leuven, Leuven, Belgium. Her research focuses on understanding the biology of selected sarcoma subtypes, the identification of potential therapeutic targets and testing of novel treatment approaches, using our unique platform of patient-derived xenograft mouse models of sarcoma (‘XenoSarc platform’), established by her group. She is also interested in identification of molecular biomarkers of response to novel cytotoxic and targeted agents, implementing high-throughput sequencing techniques to study tumor material and liquid biopsies from treated sarcoma patients. Her goal is to implement this multidisciplinary approach in research that has crucial therapeutic implications and will hopefully transform care for patients with sarcoma.

Poster(s):

• (P 43) UROKINASE PLASMINOGEN ACTIVATOR RECEPTOR-ASSOCIATED PROTEIN AS A POTENTIAL NEXT GENERATION MOLECULAR TARGET FOR TREATMENT OF GASTROINTESTINAL STROMAL TUMOR

• (P 110) GCAR1: GPNMB CAR T THERAPY FOR MIT FAMILY TRANSLOCATION POSITIVE CANCERS

• (P 254) A COLLECTION OF PATIENT-DERIVED XENOGRAFT MODELS OF GASTROINTESTINAL STROMAL TUMORS

• (P 255) EPIDEMIOLOGY OF NOVEL ACTIONABLE TARGETS IN SYNOVIAL SARCOMA: A TISSUE MICRO-ARRAY STUDY

• (P 256) EFFICACY AND TOXICITY OF VERTEPORFIN IN COMBINATION WITH PAZOPANIB TESTED IN A PATIENT-DERIVED SYNOVIAL SARCOMA XENOGRAFT

• (P 349) THE UROKINASE PLASMINOGEN ACTIVATOR RECEPTOR-ASSOCIATED PROTEIN (UPARAP) IS AN ATTRACTIVE TARGET FOR THE DEVELOPMENT OF ANTIBODY DRUG CONJUGATES FOR TREATMENT OF MESENCHYMAL MALIGNANCIES